[{"address1": "21 Ha\u2019arba\u2019a Street", "city": "Tel Aviv", "zip": "6473921", "country": "Israel", "phone": "972 3 541 3131", "fax": "972 3 541 3144", "website": "https://www.redhillbio.com", "industry": "Drug Manufacturers - Specialty & Generic", "industryKey": "drug-manufacturers-specialty-generic", "industryDisp": "Drug Manufacturers - Specialty & Generic", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.", "fullTimeEmployees": 35, "companyOfficers": [{"maxAge": 1, "name": "Mr. Dror  Ben-Asher", "age": 58, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 566465, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Razi  Ingber", "age": 40, "title": "Chief Financial Officer", "yearBorn": 1984, "fiscalYear": 2024, "totalPay": 349508, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adi  Frish", "age": 54, "title": "Chief Corporate & Business Development Officer", "yearBorn": 1970, "fiscalYear": 2024, "totalPay": 322592, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Rick D. Scruggs", "age": 64, "title": "Chief Commercial Officer & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 443736, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gilead  Raday MPhil, MSc", "age": 49, "title": "Chief Operating Officer", "yearBorn": 1975, "fiscalYear": 2024, "totalPay": 365556, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Okmian", "title": "Senior Business Development & Investor Relations Manager", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Reza  Fathi Ph.D.", "age": 69, "title": "Senior Vice President of Research & Development", "yearBorn": 1955, "fiscalYear": 2024, "totalPay": 299291, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Guy  Goldberg J.D.", "age": 48, "title": "Chief Business Officer", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 338126, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Patricia  Anderson B.Sc. RAC", "title": "Senior Vice President of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.0, "open": 2.0, "dayLow": 1.984, "dayHigh": 2.03, "regularMarketPreviousClose": 2.0, "regularMarketOpen": 2.0, "regularMarketDayLow": 1.984, "regularMarketDayHigh": 2.03, "payoutRatio": 0.0, "beta": 4.222, "trailingPE": "Infinity", "forwardPE": 67.666664, "volume": 11508, "regularMarketVolume": 11508, "averageVolume": 222100, "averageVolume10days": 16920, "averageDailyVolume10Day": 16920, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 4659540, "fiftyTwoWeekLow": 1.71, "fiftyTwoWeekHigh": 20.275, "priceToSalesTrailing12Months": 0.5793286, "fiftyDayAverage": 1.95302, "twoHundredDayAverage": 5.035585, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 25021409280, "profitMargins": -1.02797, "floatShares": 11469754846, "sharesOutstanding": 2295340, "sharesShort": 63206, "sharesShortPriorMonth": 118332, "sharesShortPreviousMonthDate": 1747267200, "dateShortInterest": 1749772800, "sharesPercentSharesOut": 0.0276, "heldPercentInsiders": 0.0, "heldPercentInstitutions": 0.05668, "shortRatio": 0.33, "shortPercentOfFloat": 0.031, "impliedSharesOutstanding": 1752010, "bookValue": -3.63, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -8268000, "trailingEps": 0.0, "forwardEps": 0.03, "lastSplitFactor": "1:25", "lastSplitDate": 1724112000, "enterpriseToRevenue": 3110.955, "enterpriseToEbitda": -2058.359, "52WeekChange": -0.76997167, "SandP52WeekChange": 0.12677538, "quoteType": "EQUITY", "currentPrice": 2.03, "recommendationKey": "none", "totalCash": 4617000, "totalCashPerShare": 0.0, "ebitda": -12156000, "totalDebt": 356000, "quickRatio": 0.337, "currentRatio": 0.536, "totalRevenue": 8043000, "revenuePerShare": 6.527, "returnOnAssets": -0.37278, "grossProfits": 4851000, "freeCashflow": -536125, "operatingCashflow": -9369000, "revenueGrowth": 3.82, "grossMargins": 0.60313, "ebitdaMargins": -1.51138, "operatingMargins": -0.69567, "financialCurrency": "USD", "symbol": "RDHL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1751571532, "regularMarketTime": 1751562000, "exchange": "NCM", "messageBoardId": "finmb_104926324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.5, "regularMarketPrice": 2.03, "longName": "RedHill Biopharma Ltd.", "shortName": "Redhill Biopharma Ltd.", "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1357569000000, "postMarketChangePercent": 0.985221, "postMarketPrice": 2.05, "postMarketChange": 0.02, "regularMarketChange": 0.03, "regularMarketDayRange": "1.984 - 2.03", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 222100, "fiftyTwoWeekLowChange": 0.31999993, "fiftyTwoWeekLowChangePercent": 0.18713446, "fiftyTwoWeekRange": "1.71 - 20.275", "fiftyTwoWeekHighChange": -18.244999, "fiftyTwoWeekHighChangePercent": -0.89987665, "fiftyTwoWeekChangePercent": -76.99717, "earningsTimestamp": 1744282805, "earningsTimestampStart": 1744282805, "earningsTimestampEnd": 1744282805, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 0.0, "epsForward": 0.03, "fiftyDayAverageChange": 0.076979995, "fiftyDayAverageChangePercent": 0.039415877, "twoHundredDayAverageChange": -3.005585, "twoHundredDayAverageChangePercent": -0.5968691, "priceToBook": -0.5592286, "marketState": "CLOSED", "displayName": "RedHill Biopharma", "trailingPegRatio": null, "__fetch_time": "2025-07-05"}]